A new study published in the journal Frontiers in Neuroscience finds that cannabidiol (CBD) may play a significant role in slowing the early progression of Alzheimer’s disease.
For the study, researchers at Loma Linda University examined how CBD influenced the molecular transition from cognitive decline to Alzheimer’s-like pathology in mice, focusing on brain and blood markers linked to the disease.
The team administered daily dietary CBD to genetically engineered Alzheimer’s mice and wild-type controls, analyzing brain regions, blood samples, and behavior. They found more than 1,000 molecular markers tied to Alzheimer’s onset, but over 75% of these were either reversed or eliminated when CBD was introduced.
The affected pathways included synaptic development and plasticity, neurovascular function, ion channels, mitochondrial genes, immune signaling, lipid synthesis, and carbohydrate metabolism. Markers such as ApoE, Fasn, Gria4, Smad9, and Ndufa7 showed notable responses. The findings suggest Alzheimer’s onset involves interconnected disruptions in inflammation, oxidative stress, insulin resistance, and lipid metabolism—factors that CBD may help regulate.
The study concludes that CBD’s broad neuroprotective effects could offer therapeutic value by addressing multiple pathological drivers of Alzheimer’s simultaneously, rather than targeting a single mechanism. While more research is needed in humans, the results strengthen the case for CBD as a candidate for future Alzheimer’s therapies.
